Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Cadila Gets First Patch Approval Amid Push Into US

Executive Summary

A generic rival to Novartis’ Exelon extended-release treatment for dementia marks Zydus Cadila’s first transdermal patch approval in the US, furthering the Indian firm’s strategy of targeting more complex delivery forms.

You may also be interested in...



Zydus Ready For Moraiya Reinspection In June

Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.

Levorphanol Write-Down Dents Zydus in Q2 But Saroglitazar Expectations Build

As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.

Analysts See More Headwinds For India’s Zydus Cadila After Quarterly Earnings Slide

Analysts said more challenges lie ahead for Zydus Cadila that will hobble earnings growth over the next couple of years, after the Indian firm reported a more than 20% slide in quarterly profit.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel